Geode Capital Management
CADX

Geode Capital Management’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Geode Capital Management’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-339,252
Closed -$3.07M – 3837
2013
Q4 		$3.07M Buy
339,252
+76,548
+29% +$553K ﹤0.01% 2045
2013
Q3 		$1.66M Buy
262,704
+24,784
+10% +$158K ﹤0.01% 2282
2013
Q2 		$1.62M Buy
+237,920
New +$1.66M ﹤0.01% 2163

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management's CADX Position: Q1 2014 in Review

Geode Capital Management sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 339,252 shares — an estimated $3.07M sold.

Geode Capital Management first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $3.07M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Geode Capital Management reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Geode Capital Management sold 339,252 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $3.07M.
  • Geode Capital Management first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Geode Capital Management's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $3.07M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Geode Capital Management's 13F filing for Q1 2014, filed 14 May 2014.